Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
13%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
1
8%
Ph early_phase_1
2
17%
Ph phase_3
3
25%
Ph not_applicable
6
50%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
2(16.7%)
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
3(25.0%)
N/ANon-phased studies
6(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(8)
Terminated(3)

Detailed Status

Completed8
Withdrawn2
Enrolling by invitation1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Early Phase 12 (16.7%)
Phase 21 (8.3%)
Phase 33 (25.0%)
N/A6 (50.0%)

Trials by Status

completed867%
enrolling_by_invitation18%
terminated18%
withdrawn217%

Recent Activity

Clinical Trials (12)

Drug Details

Intervention Type
DRUG
Total Trials
12